Jerry D. Estep et al. JCHF 2013;1:

Slides:

Advertisements

Similar presentations

Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,

Advertisements

Introduction to Ventricular Assist Device (VAD)

Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.

Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.

Ihab Alomari, MD, FACC Assistant professor – Interventional Cardiology University of California, Irvine Division of Cardiology Cath Lab Essentials : LV.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

University of Chicago Medicine

Nat. Rev. Cardiol. doi: /nrcardio

Circ Arrhythm Electrophysiol

Preoperative screening for LVAD an TAH implantation

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients James K. Kirklin, MD, David C. Naftel,

Noriko Kikuchi et al. JACEP 2016;2:

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant Jaimin R. Trivedi, MD,

The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy John W.C.

Shadi Al Halabi et al. JACEP 2015;1:

Dean J. Kereiakes et al. JACC 2017;70:

G. Michael Felker et al. JCHF 2014;2:

Robert J. Steffen, MD, Eugene H. Blackstone, MD, Nicholas G

Mechanical Circulatory Support Devices HOSEIN PASANDI.

David D. Berg et al. JACC 2018;71:

David S. Frankel et al. JACEP 2015;1:

Belinda Gray et al. JCHF 2013;1:

Nat. Rev. Cardiol. doi: /nrcardio

John E. Sanderson JCHF 2014;2:93-94

David F. Katz et al. JACEP 2016;j.jacep

Mintu P. Turakhia et al. JACEP 2016;2:

Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices Ranjit John, MD, Kenneth Liao,

Durable Mechanical Circulatory Support in Advanced Heart Failure

Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C

In vitro hemodynamic characterization of HeartMate II at 6000 rpm: Implications for weaning and recovery Gengo Sunagawa, MD, Nicole Byram, BS, Jamshid.

Wayne L. Miller et al. JCHF 2013;1:

Mohit K. Turagam et al. JACEP 2017;3:

Figure 1 Ventricular end-diastolic pressure–volume relationship curves

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant.

Yoshitaka Kimura et al. JACEP 2016;2:

Should Patients 60 Years and Older Undergo Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices? Jeremiah G. Allen, MD, Arman.

David F. Katz et al. JACEP 2017;3:20-28

Connie W. Tsao et al. JCHF 2016;4:

Neal A. Chatterjee et al. JCHF 2014;2:

Peter E. Carson et al. JCHF 2015;3:

Ayman A. Hussein et al. JACEP 2017;3:1-9

Emilce Trucco et al. JACEP 2018;j.jacep

John Rickard et al. JCHF 2013;1:

Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf

Trends in LVAD implantation rates among the Medicare population from 2004 to Trends in LVAD implantation rates among the Medicare population from.

Surabhi Madhwal et al. JIMG 2014;7:

Jay K. Bhama, MD, Utsav Bansal, BS, Daniel G. Winger, MS, Jeffrey J

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Jordan B. King et al. JCHF 2016;4:

Natasha A. Loghmanpour et al. JCHF 2016;4:

Connie W. Tsao et al. JCHF 2016;4:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Orly Vardeny et al. JCHF 2016;4:

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Kaplan-Meier estimates of all-cause mortality at 30 days.

Independent predictors of all-cause mortality at 30 days.

Mackram F. Eleid et al. JIMG 2016;9:

Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.

Changes in clinical parameters and use of catecholamines during hospitalisation (A) inotropic score, B) serum lactate levels and (C) SAPS II from baseline.

Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.

Constantijn Franssen et al. JCHF 2016;4:

Presentation transcript:

Jerry D. Estep et al. JCHF 2013;1:382-388 Patient Outcomes Values are median (range) days of support. *All 4 deaths occurred while patients were on a waiting list(s) due to multiorgan failure (13 [10–40] days), with 1 patient listed for repeat transplantation (40 days). †Three patients had progressive heart failure (HF): 1 with ventricular tachycardia/fibrillation (VT/VF), 1 with concomitant acute renal failure both requiring high-risk left ventricular assist device (LVAD) (50 [37–63] days), and 1 with progressive biventricular HF requiring high-risk total artificial heart implantation after remote orthotopic heart transplantation (OHT) (37 days). ‡One patient underwent intra-aortic balloon pump (IABP) removal due to bleeding after 60 days of support and received an OHT as status 1B by exemption. §Median (range) days of support: 15 (4–61) days. ‖Median (range) days of support: 23 (12–133) days. ¶Median (range) days of support: 98 (44–152) days. BTT = bridge to transplantation. Heartmate II is a trademark of Thoratec Corporation (Pleasanton, California). Jerry D. Estep et al. JCHF 2013;1:382-388 American College of Cardiology Foundation